Business

Boehringer Ingelheim said recently that it has completed a €105 million expansion of its facilities in Dortmund and Ingelheim, Germany to increase manufacturing capacity for its Respimat soft mist inhaler. The company said that the… Read more . . .

Following Pulmatrix’s recent successful public offering, Pulmatrix and Cipla subsidiary Cipla Technologies (Cip Tec) have entered into a definitive agreement in which Cipla will acquire rights to the Pulmazole itraconazole DPI for the treatment of… Read more . . .

Cipla Limited has announced the launch of its Niveoli extra-fine particle beclomethasone/formoterol fumarate MDI for the treatment of asthma and COPD in adults in India. Cipla India Business Head Nikhil Chopra commented, “Cipla is pleased… Read more . . .

Insmed Incorporated said that the U.S. Patent and Trademark Office (USPTO) has issued US patent No. 10,251,900, titled “Methods for treating pulmonary non-tuberculous mycobacterial infections,” which is the 10th US patent covering the use of… Read more . . .

Noveome Biotherapeutics said that it has closed a $15 million Series D financing round that will help to fund further development of its ST266 biologic. Intranasal formulations of ST266 are in development for the treatment… Read more . . .

Pulmatrix said that it has closed a public offering with expected gross proceeds of $16.6 million that will be used primarily for development of its inhaled therapies, especially Pulmazole inhaled itraconazole for the treatment of… Read more . . .

Endo International has announced that its subsidiary Endo Procurement Operations Limited recently reached an agreement with Merck to distribute an authorized generic of Proventil HFA albuterol sulfate MDI in the US. Endo operating company Par… Read more . . .

Opiant Pharmaceuticals has received an additional $3 million from a 3-year grant awarded in 2018 by the National Institutes of Health’s (“NIH”) National Institute on Drug Abuse (“NIDA”) to support development of OPNT003 intranasal nalmefene… Read more . . .